Our discovery that UGP2 acts as a tumor-suppressive factor in CRC indicates that its downregulation drives malignant progression and is associated with poor clinical outcomes, highlighting its potential as a dual-purpose diagnostic and prognostic candidate biomarker. This evidence concerns the gene UGP2 and colorectal carcinoma.